Authorized purpose: Aid pediatric radiologists in assessing bone age from PA left-hand radiographs for patients aged 2-16 years; the result is an adjunct and must not be used alone for diagnostic decisions.
Clinical role
Quantitative bone-age assessment adjunct during concurrent radiograph review in a PACS client or workstation; the original image remains available and the output is not the primary interpretation.
Images and patients
X-ray/Radiography · Left hand and wrist / skeletal age
Key limitation
Keep in mind: The labeled population is patients aged 2-16 years and the labeled image is a 2D PA left-hand radiograph. Full hand and wrist visibility and acceptable image quality are required. Pediatric radiologist review and clinical judgment remain required; the software output must not be used as the primary interpretation or alone for diagnostic decisions.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Aid pediatric radiologists in assessing bone age from PA left-hand radiographs for patients aged 2-16 years; the result is an adjunct and must not be used alone for diagnostic decisions.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Left hand and wrist / skeletal age Input: DICOM-standard-compliant 2D PA left-hand radiographs for patients aged 2-16 years, with the full left hand and wrist in the field of view and without major bone destruction, deformity, fracture, excessive motion, or other major artifacts.
Who uses it?Intended users: Pediatric radiologists
What does the software produce?Output: A standard JSON message containing the estimated bone age in years; the result can be transferred to and processed by RIS, HIS, PACS, and other workstations, with the original unaltered radiograph available in the same study.
What is its most important limitation?Key limitation: The labeled population is patients aged 2-16 years and the labeled image is a 2D PA left-hand radiograph. Full hand and wrist visibility and acceptable image quality are required. Pediatric radiologist review and clinical judgment remain required; the software output must not be used as the primary interpretation or alone for diagnostic decisions.
Clinical takeaway. Clinical role: Aid pediatric radiologists in assessing bone age from PA left-hand radiographs for patients aged 2-16 years; the result is an adjunct and must not be used alone for diagnostic decisions.
Evidence takeaway. Evidence from the reviewed source record: FDA K234042 reports nonclinical development data from 26,222 cases, including 23,578 training and 2,644 testing cases, and a standalone study of 600 independent left-hand PA radiographs from 27 US locations. Ground truth used four US board-certified expert radiologists and Greulich-Pyle comparison. The primary endpoint was Deming-regression intercept and slope: intercept -0.07 (95% CI -0.13 to -0.01) and slope 1.00 (95% CI 0.99-1.00); over 88% of cases differed from ground truth by less than 0.5 years, with Bland-Altman 95% limits of agreement of -0.517 to 0.743 years.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Aid pediatric radiologists in assessing bone age from PA left-hand radiographs for patients aged 2-16 years; the result is an adjunct and must not be used alone for diagnostic decisions.
Quantitative bone-age assessment adjunct during concurrent radiograph review in a PACS client or workstation; the original image remains available and the output is not the primary interpretation.
DICOM-standard-compliant 2D PA left-hand radiographs for patients aged 2-16 years, with the full left hand and wrist in the field of view and without major bone destruction, deformity, fracture, excessive motion, or other major artifacts.
A standard JSON message containing the estimated bone age in years; the result can be transferred to and processed by RIS, HIS, PACS, and other workstations, with the original unaltered radiograph available in the same study.
The labeled population is patients aged 2-16 years and the labeled image is a 2D PA left-hand radiograph. Full hand and wrist visibility and acceptable image quality are required. Pediatric radiologist review and clinical judgment remain required; the software output must not be used as the primary interpretation or alone for diagnostic decisions.
FDA K234042 reports nonclinical development data from 26,222 cases, including 23,578 training and 2,644 testing cases, and a standalone study of 600 independent left-hand PA radiographs from 27 US locations. Ground truth used four US board-certified expert radiologists and Greulich-Pyle comparison. The primary endpoint was Deming-regression intercept and slope: intercept -0.07 (95% CI -0.13 to -0.01) and slope 1.00 (95% CI 0.99-1.00); over 88% of cases differed from ground truth by less than 0.5 years, with Bland-Altman 95% limits of agreement of -0.517 to 0.743 years.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K234042 reports nonclinical development data from 26,222 cases, including 23,578 training and 2,644 testing cases, and a standalone study of 600 independent left-hand PA radiographs from 27 US locations. Ground truth used four US board-certified expert radiologists and Greulich-Pyle comparison. The primary endpoint was Deming-regression intercept and slope: intercept -0.07 (95% CI -0.13 to -0.01) and slope 1.00 (95% CI 0.99-1.00); over 88% of cases differed from ground truth by less than 0.5 years, with Bland-Altman 95% limits of agreement of -0.517 to 0.743 years.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
EFAI Bonesuite XR Bone Age Pro Assessment System (BAP-XR-100) regulatory performance study summary
DesignStand-Alone Performance
PopulationPediatric
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K234042
Samplen=600
Sites27
IndependenceIndependence not established
K234042
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K234042. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM-standard-compliant 2D PA left-hand radiographs for patients aged 2-16 years, with the full left hand and wrist in the field of view and without major bone destruction, deformity, fracture, excessive motion, or other major artifacts.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The packet describes DICOM input, a PACS client or workstation workflow, and JSON output transferable to RIS/HIS/PACS and other workstations. Specific interfaces, versions, and current deployment configuration are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: A standard JSON message containing the estimated bone age in years; the result can be transferred to and processed by RIS, HIS, PACS, and other workstations, with the original unaltered radiograph available in the same study.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A standard JSON message containing the estimated bone age in years; the result can be transferred to and processed by RIS, HIS, PACS, and other workstations, with the original unaltered radiograph available in the same study.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The packet describes DICOM input, a PACS client or workstation workflow, and JSON output transferable to RIS/HIS/PACS and other workstations. Specific interfaces, versions, and current deployment configuration are not established.
Ever Fortune.AI's investor information-security policy page states an implemented information security management system covering confidentiality, integrity, and availability, with security training and measurement targets; the page states the company has completed ISO 27001 certification and holds ISO/IEC 27701 PII-processor certification after independent third-party audit. The company's certification-milestones page lists ISO/IEC 27001:2022, ISO 22301:2019, ISO/IEC 27018:2019, and ISO/IEC 27017:2015.
Vendor-wide
Checked 2026-10-27
Vendor statement; certificates were not read. Applicant name variants (including uppercase and punctuation variants of Ever Fortune.AI Co., Ltd.) are bridged via the vendor's EFAI product naming and the owning domain everfortuneai.com.tw. Exact-release scope is not established.
ACR AI Central provides an exact-submission model card for EFAI Bonesuite XR Bone Age Pro Assessment System (BAP-XR-100); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K234042 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Opportunistic review of frontal lumbar-spine or KUB radiographs in adults aged 50 years and older to flag possible low bone mineral density at L1-L4 for clinician follow-up; a negative result does not rule out low BMD.
Authorized purpose: Rayvolve supports clinicians by identifying suspected fractures, joint effusions, and dislocations on labeled radiographic views; it does not replace clinician interpretation.
Modality
X-ray/Radiography
Anatomy
Musculoskeletal and chest/ribs radiographs across specified views
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.
Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.